Observational analysis examines treatment de-escalation in breast cancer, suggesting need for tailored approaches.
This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, studies evaluate the de‐escalation of treatment for certain patients with breast cancer. In addition, no overall survival benefit was found when adding venetoclax for patients with relapsed or refractory multiple myeloma, and APOLLO trial confirms ATRA—ATO use for patients with high‐risk acute promyelocytic leukemia.
No takes yet. Share an insight, caveat, or question.
Leah Lawrence (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: